Sotalol as Adjunctive Therapy to Implantable Cardioverter-Defibrillators in Heart Failure Patients
Article first published online: 1 APR 2009
© 2009 Wiley Periodicals, Inc.
Congestive Heart Failure
Volume 15, Issue 3, pages 144–147, May/June 2009
How to Cite
Chaki, A. L., Caines, A. E. and Miller, A. B. (2009), Sotalol as Adjunctive Therapy to Implantable Cardioverter-Defibrillators in Heart Failure Patients. Congestive Heart Failure, 15: 144–147. doi: 10.1111/j.1751-7133.2009.00062.x
- Issue published online: 12 MAY 2009
- Article first published online: 1 APR 2009
- Manuscript received August 11, 2008; revised December 29, 2008; accepted February 2, 2009
The number of heart failure patients with implantable cardioverter-defibrillators is rising. Common issues encountered in this population are high defibrillation thresholds and inappropriate shocks. In order to resolve these problems, the addition of a class III antiarrhythmic such as sotalol is often considered. Given the emerging issue of polypharmacy and medication compliance in the heart failure population, the question of the efficacy of sotalol in reducing inappropriate shocks, defibrillation thresholds, and its ability to replace conventional β-blockers is often raised. Current literature review suggests that sotalol is a useful adjunct to the contemporary heart failure regimen. It has the ability to reduce inappropriate shocks and defibrillation thresholds, but appears not to fully reproduce the pleiotropic beneficial effects of the β-blockers more commonly employed for their mortality/remodeling benefits in heart failure patients.